Aberrant glycogen synthase kinase 3β in the development of pancreatic cancer

@inproceedings{Shimasaki2012AberrantGS,
  title={Aberrant glycogen synthase kinase 3β in the development of pancreatic cancer},
  author={Takeo Shimasaki and Ayako Kitano and Yoshiharu Motoo and Toshinari Minamoto},
  booktitle={Journal of carcinogenesis},
  year={2012}
}
Development and progression of pancreatic cancer involves general metabolic disorder, local chronic inflammation, and multistep activation of distinct oncogenic molecular pathways. These pathologic processes result in a highly invasive and metastatic tumor phenotype that is a major obstacle to curative surgical intervention, infusional gemcitabine-based chemotherapy, and radiation therapy. Many clinical trials with chemical compounds and therapeutic antibodies targeting growth factors… CONTINUE READING
BETA

Similar Papers

References

Publications referenced by this paper.
SHOWING 1-10 OF 113 REFERENCES

Deregulated GSK3{beta} sustains gastrointestinal cancer cells survival by modulating human telomerase reverse transcriptase and telomerase.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2009
VIEW 8 EXCERPTS
HIGHLY INFLUENTIAL

Potential therapeutic effect of glycogen synthase kinase 3beta inhibition against human glioblastoma.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2009
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL